LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 1 of 15: Cell count and relative growth within biological replicate 1. - Dataset (ID:20237)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Seliciclib | 10.0 | uM | LJP5 | 3 | J01 | 72 | hr | 1476 | 1442 | 3694 | 0.3904 | -0.0157 |
| SK-BR-3 | Ruxolitinib | 10.0 | uM | LJP5 | 1 | O13 | 72 | hr | 1476 | 2606 | 3694 | 0.7055 | 0.5093 |
| SK-BR-3 | Ruxolitinib | 10.0 | uM | LJP5 | 2 | O13 | 72 | hr | 1476 | 2780 | 3694 | 0.7526 | 0.5878 |
| SK-BR-3 | Ruxolitinib | 10.0 | uM | LJP5 | 3 | O13 | 72 | hr | 1476 | 2970 | 3694 | 0.8040 | 0.6735 |
| SK-BR-3 | XL147 | 10.0 | uM | LJP5 | 1 | G07 | 72 | hr | 1476 | 2647 | 3694 | 0.7166 | 0.5278 |
| SK-BR-3 | XL147 | 10.0 | uM | LJP5 | 2 | G07 | 72 | hr | 1476 | 2894 | 3694 | 0.7834 | 0.6392 |
| SK-BR-3 | XL147 | 10.0 | uM | LJP5 | 3 | G07 | 72 | hr | 1476 | 2923 | 3694 | 0.7913 | 0.6523 |
| SK-BR-3 | Saracatinib | 10.0 | uM | LJP6 | 1 | D07 | 72 | hr | 1476 | 2057 | 3694 | 0.5568 | 0.2617 |
| SK-BR-3 | Saracatinib | 10.0 | uM | LJP6 | 2 | D07 | 72 | hr | 1476 | 1847 | 3694 | 0.5000 | 0.1670 |
| SK-BR-3 | Saracatinib | 10.0 | uM | LJP6 | 3 | D07 | 72 | hr | 1476 | 2002 | 3694 | 0.5420 | 0.2369 |
| SK-BR-3 | Selumetinib | 10.0 | uM | LJP6 | 1 | M07 | 72 | hr | 1476 | 3238 | 3694 | 0.8765 | 0.7943 |
| SK-BR-3 | Selumetinib | 10.0 | uM | LJP6 | 2 | M07 | 72 | hr | 1476 | 3641 | 3694 | 0.9856 | 0.9761 |
| SK-BR-3 | Selumetinib | 10.0 | uM | LJP6 | 3 | M07 | 72 | hr | 1476 | 3687 | 3694 | 0.9981 | 0.9968 |
| SK-BR-3 | Sirolimus | 10.0 | uM | LJP6 | 1 | L13 | 72 | hr | 1476 | 1833 | 3694 | 0.4962 | 0.1607 |
| SK-BR-3 | Sirolimus | 10.0 | uM | LJP6 | 2 | L13 | 72 | hr | 1476 | 2306 | 3694 | 0.6243 | 0.3740 |
| SK-BR-3 | Sirolimus | 10.0 | uM | LJP6 | 3 | L13 | 72 | hr | 1476 | 2470 | 3694 | 0.6686 | 0.4480 |
| SK-BR-3 | Sorafenib | 10.0 | uM | LJP6 | 1 | B07 | 72 | hr | 1476 | 2031 | 3694 | 0.5498 | 0.2500 |
| SK-BR-3 | Sorafenib | 10.0 | uM | LJP6 | 2 | B07 | 72 | hr | 1476 | 1647 | 3694 | 0.4459 | 0.0768 |
| SK-BR-3 | Sorafenib | 10.0 | uM | LJP6 | 3 | B07 | 72 | hr | 1476 | 1514 | 3694 | 0.4099 | 0.0168 |
| SK-BR-3 | SU11274 | 10.0 | uM | LJP5 | 1 | J07 | 72 | hr | 1476 | 1474 | 3694 | 0.3990 | -0.0012 |
| SK-BR-3 | SU11274 | 10.0 | uM | LJP5 | 2 | J07 | 72 | hr | 1476 | 1495 | 3694 | 0.4047 | 0.0082 |
| SK-BR-3 | SU11274 | 10.0 | uM | LJP5 | 3 | J07 | 72 | hr | 1476 | 1438 | 3694 | 0.3893 | -0.0175 |
| SK-BR-3 | Fedratinib | 10.0 | uM | LJP5 | 1 | L01 | 72 | hr | 1476 | 1072 | 3694 | 0.2902 | -0.1825 |
| SK-BR-3 | Fedratinib | 10.0 | uM | LJP5 | 2 | L01 | 72 | hr | 1476 | 1055 | 3694 | 0.2856 | -0.1902 |
| SK-BR-3 | Fedratinib | 10.0 | uM | LJP5 | 3 | L01 | 72 | hr | 1476 | 1406 | 3694 | 0.3806 | -0.0319 |